A team of serial investors have spun a new venture out of tumor-fighting technology developed at Yale University. Venture capitalists Per Hellsund, Kevin Rakin and Kevin Didden — who have led half a dozen businesses that sold for more than a combined $1 billion — launched Cybrexa this year after raising $6 million from individuals, investment firms and Connecticut Innovations, the state’s enterprise-funding entity … more

In a Q&A interview, Hartford Business recently talked with Per Hellsund, president & CEO of New Haven-based Cybrexa Therapeutics, which recently raised $6 million to advance its cancer research … more